Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Thérese Sørlie, Charles M. Perou, Robert Tibshirani, +14

Proceedings of the National Academy of Sciences

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

Lucy Yates, Moritz Gerstung, Stian Knappskog, +34

Nature Medicine

Breast OncologyOncologyTumor HeterogeneityMedicinePathology +6

Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

Turid Aas, Anne‐Lise Børresen, Stephanie Geisler, +5

Nature Medicine

Breast OncologyBreast Cancer PatientsMedicinePathologyCancer Genomics +7

Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays

Jonathan R. Pollack, Charles M. Perou, Thérese Sørlie, +13

Nature Genetics

Breast OncologyTumor HeterogeneityMedicineGeneticsDna Microarrays +7

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Stephanie Geisler, Per Eystein Lønning, Turid Aas, +5

PubMed

Breast OncologyC-erbb-2 ExpressionPathologyCancer BiologyTumor Biology +16

Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.

Karin Collett, Geir Egil Eide, Jarle B. Arnes, +6

Clinical Cancer Research

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

Hans Petter Eikesdal, Synnøve Yndestad, Ahmed El‐Zawahry, +19

Annals of Oncology

TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.

Stephanie Geisler, Anne‐Lise Børresen‐Dale, Hilde Johnsen, +5

PubMed

DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

Emelyne Dejeux, Jo Anders Rønneberg, Hiroko Kato Solvang, +7

Molecular Cancer

Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels

Jürgen Geisler, Hilgegunn Helle, Dagfinn Ekse, +5

Clinical Cancer Research